Aethlon Medical Announces West Nile Research Collaboration.

SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it will initiate studies to test the in vitro effectiveness of the Aethlon Hemopurifier[R] to capture West Nile virus (WNV), an infectious disease presently untreatable with antiviral drug and vaccine therapy. The studies are designed to evaluate the potential of the Hemopurifier[R] to treat WNV, and to further demonstrate the broad-spectrum effectiveness of the Hemopurifier[R] to capture viral pathogens.

Therapies able to demonstrate broad-spectrum effectiveness against multiple pathogens have recently been mandated by the U.S. Department of Health and Human Services (HHS) to be the focal point of government programs that support the commercialization of candidate countermeasures against bioterror and pandemic threats. Aethlon Medical considers the Hemopurifier[R] to be the leading broad-spectrum candidate as evidenced by its breadth of pre-clinical data and human treatment experience. Data resulting from the WNV study and other clinical programs will be included in a forthcoming submission to HHS and the newly established Biomedical Research and Development Authority (BARDA) to advance the commercialization of the Hemopurifier[R] as a broad-spectrum countermeasure against bioterror and pandemic threats.

The WNV studies will be conducted at the Battelle Biomedical Research Center, a global research organization who previously collaborated with Aethlon Medical on pre-clinical testing of the Hemopurifier[R] against the highly fatal H5N1 Avian Flu Virus (bird flu). In those studies, the Hemopurifier[R] proved effective in removing up to 99.4% of infectious H5N1 from cell culture fluids during a six-hour testing periods.

WNV first appeared in the Western hemisphere in 1999, and is believed to have entered via an infected bird or mosquito, the primary vector for human infection. Incidence of infection within the U.S. has since increased with approximately 3,600 cases reported in 2007, 33 percent of which were the more severe neuro-invasive forms, and these resulted in 121 fatalities. It is further believed that there is a significant underreporting of the number of actual cases. The cost of West Nile related health care in the U.S. exceeded $200 million in the 2002 alone.

About Battelle Biomedical Research Center

Battelle is the world's largest non-profit independent research and development organization, providing innovative solutions to the world's most pressing needs through its four global businesses: laboratory management, national security, energy technology and health and life sciences. It advances scientific discovery and application by conducting $4 billion in global R&D annually through contract research, laboratory management and technology commercialization. Headquartered in Columbus, Ohio, Battelle oversees 20,400 employees in more than 120 locations worldwide, including seven national laboratories that Battelle manages or co-manages for the U.S. Department of Energy and the U.S. Department of Homeland Security. Battelle is also one of the nation's leading charitable trusts focusing on societal and economic impact and actively supporting and promoting science and math education. For more information, visit www.battelle.org.

About Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier[R], a first-in-class medical device designed to treat infectious disease. The Hemopurifier[R] provides real-time therapeutic filtration of infectious viruses and immunosuppressive particles, and is positioned to address the treatment of drug and vaccine resistant viruses. The device also holds promise in cancer care, as research studies have verified the Hemopurifier[R] able to capture immunosuppressive particles that are secreted by tumors. The Hemopurifier[R] is targeted for use a stand-alone therapeutic, and as an adjunct treatment to enhance clinical benefit of established and candidate therapies. Pre-clinical studies conducted by researchers representing leading government and non-government health organizations both in the United States and abroad have documented the effectiveness of the Hemopurifier[R] in capturing pandemic threats, including H5N1 Avian Influenza (bird flu), and Dengue Hemorrhagic Fever (DHF) from circulation. Studies are also being conducted to support the use of the Hemopurifier[R] as a broad-spectrum treatment countermeasure against bioterror threats, including Smallpox, and Ebola, Marburg, and Lassa hemorrhagic fever. Regulatory and commercialization initiatives in the United States are presently focused on bioterror threats, while international initiatives are directed toward naturally evolving pandemic threats, and chronic infectious disease conditions including the Human Immunodeficiency Virus (HIV) and Hepatitis-C (HCV). Aethlon has previously demonstrated safety of the Hemopurifier[R] in a 24-treatment human study at the Apollo Hospital in Delhi, India, and is currently conducting further human studies at the Fortis Hospital, also located in Delhi. The Company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) related to advancing the Hemopurifier([R])as a broad-spectrum treatment countermeasure against category "A" bioterror threats. Additional information regarding Aethlon Medical and its Hemopurifier([R]) technology is available online at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.